Eagle Pharmaceuticals (EGRX) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

EGRX · Stock Price

USD 0.38-1.61 (-80.90%)

Market Cap: $3.3M

Historical price data

Market Cap: $3.3MPipeline: 8 drugs (2 Phase 3)Founded: 2007HQ: Woodcliff Lake, United States

Sector Ranking#370 in Small Molecule Drugs

Overview

Eagle Pharmaceuticals is a specialty pharmaceutical company with a strategic focus on critical care and oncology, dedicated to discovering, developing, and marketing medicines that matter. The company has transitioned from a portfolio-based model to one with a diversified pipeline of internally and externally sourced candidates, including novel new chemical entities. Recent strategic moves include the divestiture of BARHEMSYS to sharpen its focus on its core pipeline and commercial assets like BYFAVO.

Critical CareOncology

Technology Platform

A development-focused platform centered on novel pharmaceutical formulation science and regulatory strategy to optimize existing therapies and advance new chemical entities (NCEs), particularly for acute care settings.

Pipeline

8

8 drugs in pipeline2 in Phase 3

Drug	Indication	Stage
Arm 1 Cataract Surgery performed with remimazolam as sedativ...	Cataract Surgery Anesthesia	Approved
Placebo + Mesalamine + Mesalamine	Mild to Moderate Ulcerative Colitis	Phase 3
Ryanodex and Standard of Care	Exertional Heat Stroke	Phase 3
CAL02 + Placebo	Pneumonia, Bacterial	Phase 2
Ryanodex (dantrolene sodium) for injectable suspension	Drug Toxicity Psychotropic Agents Psychostimulants	Phase 2

Funding History

1

Total raised:$60M

IPO$60MUndisclosedFeb 6, 2014

Opportunities

Eagle has the opportunity to leverage its acute care commercial expertise to drive adoption of BYFAVO and future pipeline products in the large hospital market.

Its first-in-class NCE pipeline in oncology and critical care represents a potentially high-reward avenue for creating significant value if clinical candidates demonstrate positive proof-of-concept.

Risk Factors

Key risks include clinical failure of its lead pipeline candidates, commercial execution challenges in competitive hospital markets, and financial sustainability given the costs of drug development.

The company's value is concentrated in a small number of assets.

Competitive Landscape

Eagle competes with large pharma and generic companies in established markets like sedation, and will face competition from other biotechs and pharma for its novel pipeline assets. Its edge lies in targeted development, formulation expertise, and focused commercial execution in acute care.